<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003948</url>
  </required_header>
  <id_info>
    <org_study_id>IBO-METAD-001</org_study_id>
    <nct_id>NCT04003948</nct_id>
  </id_info>
  <brief_title>Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification</brief_title>
  <official_title>Preliminar Efficacy and Safety of Ibogaine in the Treatment of Methadone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Center for Ethnobotanical Education, Research, and Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Multidisciplinary Association for Psychedelic Studies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Rovira i Virgili</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Autonoma de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Center for Ethnobotanical Education, Research, and Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methadone is a very long-acting opiate very difficult to detox from. In Spain there are a lot&#xD;
      of methadone dependent people in the aftermath of the heroin epidemic of the 1980s. Many have&#xD;
      been dependent for more than 15 years and a number of them have a relatively stable life&#xD;
      condition (have work, family, housing, etc.) and a relatively good health condition in&#xD;
      comparison with current heroin users. This Phase-II RCT is a collaboration with the Sant Joan&#xD;
      Hospital in Reus, Spain. Twenty patients on the methadone maintenance program will be&#xD;
      recruited. Patients will be randomized to two groups: One receiving 6 doses of 100 mg of&#xD;
      ibogaine; and the other one receiving ascending doses of ibogaine (100-200-300-400-500-600).&#xD;
      Methadone use will be interrupted and for both groups ibogaine will be administered when&#xD;
      clinical symptoms of opioid withdrawal appear. After an ibogaine dose, when symptoms of&#xD;
      opioid withdrawal appear again, half of the methadone dose used last time will be&#xD;
      administered. By doing so, methadone doses will be progressively reduced until no withdrawal&#xD;
      symptoms appear.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methadone dose</measure>
    <time_frame>0-6 months</time_frame>
    <description>Rate of decrease of methadone dose used</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Description of adverse events found at different doses of ibogaine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular effects</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Electrocardiogram (QT interval, ST wave)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Drug Dependence</condition>
  <condition>Drug Use Disorders</condition>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Fixed dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibogaine Hydrochloride 100 mg on each administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibogaine Hydrochloride on ascending doses (100-200-300-400-500-600).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibogaine Hydrochloride</intervention_name>
    <description>Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.</description>
    <arm_group_label>Ascending dose</arm_group_label>
    <arm_group_label>Fixed dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 and 60 years.&#xD;
&#xD;
          -  Body weight within normal range (Quetelet's index between 19 and 27) expressed as&#xD;
             weight (kg) / height (m2).&#xD;
&#xD;
          -  Normal clinical records and physical examination.&#xD;
&#xD;
          -  Subjects without organic disorders.&#xD;
&#xD;
          -  Laboratory tests (hematology, biochemistry and urinalysis) within the range of normal&#xD;
             values, according to the laboratory reference values of the &quot;Hospital Universitari&#xD;
             Sant Joan de Reus&quot;. Variations may be admitted according to the clinical criteria of&#xD;
             the Principal Investigator.&#xD;
&#xD;
          -  Clinically acceptable temperature, blood pressure and pulse rate in supine and&#xD;
             standing position (SBP between 100-140 mm Hg/ DBP between 50-90 mm Hg / HR between&#xD;
             50-100 bpm). Blood pressure and pulse will be measured after a minimum of 3 minutes of&#xD;
             resting.&#xD;
&#xD;
          -  Having not participated in another clinical trial in the last 2 months.&#xD;
&#xD;
          -  Free acceptance to participate in the study by obtains signed informed consent form&#xD;
             approved by the ethics committee.&#xD;
&#xD;
          -  ECG values within the range of normal values (PR &lt; 240 ms, QRS &lt; 110 ms and QTc &lt; 430&#xD;
             ms in men and QTc &lt; 450 ms in women, and heart rate &gt;50 bpm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Background of allergy, idiosyncrasy or hypersensitivity to drugs..&#xD;
&#xD;
          -  Intake of any medication within 2 weeks prior taking the study treatment (except for&#xD;
             use of paracetamol in short-term symptomatic treatments), including over-the-counter&#xD;
             products (including natural food supplements, vitamins and medicinal plants products),&#xD;
             or any enzymatic inductor or inhibitor before the drug administration.&#xD;
&#xD;
          -  Viral activity for hepatitis B, C or HIV.&#xD;
&#xD;
          -  Background or clinical evidence of cardiovascular, respiratory, renal, hepatic,&#xD;
             endocrine, gastrointestinal, hematological or neurological disease or other chronic&#xD;
             diseases.&#xD;
&#xD;
          -  History of severe psychiatric disease like psychosis, bipolar disorder or dissociative&#xD;
             disorders, or a high risk to develop them as reported by psychometric questionnaires.&#xD;
&#xD;
          -  Past or current risk of suicide.&#xD;
&#xD;
          -  Having undergone major surgery during the previous 6 months before the enrollment.&#xD;
&#xD;
          -  Positive results of the drugs at screening period or the day before starting treatment&#xD;
             period: Amphetamines, Cocaine, Ethanol, Opiates (not methadone), and not prescribed&#xD;
             Benzodiazepines (positive results may be repeated at the discretion of the PI).&#xD;
&#xD;
          -  Not understanding the nature of the study and potential consequences.&#xD;
&#xD;
          -  12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440 msec&#xD;
             for men and ≥450 for women, bradycardia (&lt;50 bpm) or clinically significant minor ST&#xD;
             wave changes or any other abnormal changes on the screening ECG that would interfere&#xD;
             with measurement of the QT interval.&#xD;
&#xD;
          -  Pregnancy or lactation status (females).&#xD;
&#xD;
          -  Not understanding the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Carlos Bouso, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Center for Ethnobotanical Education, Research, and Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tre Borràs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Sant Joan de Reus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Genís Ona, MSc</last_name>
    <role>Study Director</role>
    <affiliation>International Center for Ethnobotanical Education, Research, and Service</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genís Ona, MSc</last_name>
    <phone>675553344</phone>
    <phone_ext>+34</phone_ext>
    <email>genisona@iceers.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>José Carlos Bouso, PhD</last_name>
    <email>jcbouso@iceers.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tre Borras, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ibogaine</keyword>
  <keyword>Methadone</keyword>
  <keyword>Drug dependence</keyword>
  <keyword>Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibogaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

